We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




Glycemic Markers Influenced by Chronic Kidney Disease

By LabMedica International staff writers
Posted on 18 Feb 2020
Print article
Image: The ABX Pentra 400 is a compact clinical chemistry benchtop autoanalyzer (Photo courtesy of Horiba Medical).
Image: The ABX Pentra 400 is a compact clinical chemistry benchtop autoanalyzer (Photo courtesy of Horiba Medical).
Chronic kidney disease (CKD) is estimated to affect about 10% of the general adult population and is even more prevalent in diabetic patients. It is estimated that 20%–40% of individuals with diabetes have moderate to severe CKD, ranking diabetes as the leading cause of end-stage renal disease (ESRD) and an important risk factor for morbidity and mortality in dialysis patients.

It is known that good glycemic control predicts better clinical outcomes for patients with diabetes, by limiting morbidity and mortality associated with cardiovascular complications and end-organ damage. It has been suggested that the relationship between glycated hemoglobin A1c (HbA1c) and blood glucose concentration is altered as the glomerular filtration rate (GFR) declines.

Scientists at the South African Medical Research Council (Cape Town, South Africa) and their colleagues assess whether the agreement between fasting glucose and glycated proteins is affected by chronic kidney disease (CKD) in a community-based sample of 1,621 mixed-ancestry South Africans. A standard oral glucose tolerance test (OGTT) was performed by drawing a blood sample after an overnight fast, as well as two hours after a 75 g oral glucose load, to determine plasma glucose and serum insulin concentrations.

Plasma glucose levels were measured by enzymatic hexokinase method (Beckman AU, Beckman Coulter, Midrand, South Africa) and serum insulin with a paramagnetic particle chemiluminescence assay (Beckman DXI). HbA1c was analyzed with high-performance liquid chromatography (Bio-Rad Variant Turbo, Bio-Rad, Cape Town, South Africa), whereas hemoglobin was measured on a Coulter LH 750 hematology analyzer and fructosamine was determined by immunoturbidimetry on an ABX Pentra 400 autoanalyzer (Horiba Medical, Irvine, CA, USA).

The investigators reported that of those 96 with CKD, 79%, 16% and 5% where in stages 3, 4 and 5, respectively. Those with CKD had higher levels of HbA1c (6.2% versus 5.7%), glycated albumin (15.0% versus 13.0%) and fructosamine levels (269.7 versus 236.4 μmol/L), compared to those without CKD. Higher fasting glucose levels were associated with higher HbA1c, glycated albumin and fructosamine, independent of age, gender, and CKD. However, the association with HbA1c and glycated albumin differed by CKD status, at the upper concentrations of the respective markers.

The authors concluded that though HbA1c and glycated albumin perform acceptably under conditions of normoglycemia, but their findings suggest that these markers significantly underestimate true glycemic levels in people with CKD, not on dialysis. The results suggest that fructosamine may potentially be a more reliable marker of glycemic levels in those with CKD with elevated fasting blood glucose. The study was published on January 30, 2020 in the journal BMC Nephrology.

Related Links:
South African Medical Research Council
Beckman Coulter
Bio-Rad
Horiba Medical


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Uric Acid and Blood Glucose Meter
URIT-10

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.